Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc. is a mRNA manufacturing device founded in 2017 by Igor Khandros.
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Company
Organization
CEO
Igor Khandros
0
CFO
James Zhu
CIK Number
1,741,042
Legal Name
Nutcracker Therapeutics, Inc.
Company Operating Status
Active
Competitors
ConcertAI LLC
Remix Therapeutics
COO
Madhavan Balachandran
Country
United States
0
Crunchbase URL
crunchbase.com/organiz...apeutics
CTO
Benjamin Eldridge
0
Date Incorporated
2017
Founded Date
2017
Founder
Benjamin Eldridge
0
Igor Khandros
0
Full Address
5858 Horton Street, Suite 540 Emeryville, CA 94608
0
Industry
Biopharmaceutical
Biomedical engineering
Engineering
Technology
Biology
Biotechnology
Investors
Altitude Life Science Ventures
0
ARCH Venture Partners
BlueBird Ventures
Key People
Pin Kao
Swami Murugappan
Geoff Nosrati
Guna Kannan
Christine Wu
Samuel Deutsch
Ian Wiener
Michelle Roth
Latest Funding Round Date
September 2021
Latest Funding Type
Series B Round
Legal classification
Corporation
LinkedIn URL
@company/nutcracker-therapeutics
Location
Emeryville, California
0
San Francisco
Number of Employees
102
0
Number of Employees (Ranges)
51 – 200
Patents Assigned (Count)
1
Phone Number
+14159060733
0
Pitchbook URL
pitchbook.com/profiles...234939-43
Place of Incorporation
Delaware
Total Funding Amount (USD)
334,936,834
Official Website
nutcrackerx.com
Find more companies like Nutcracker Therapeutics, Inc.
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE